Growth Metrics

Halozyme Therapeutics (HALO) Goodwill & Intangibles (2022 - 2026)

Halozyme Therapeutics has reported Goodwill & Intangibles over the past 5 years, most recently at $1.5 billion for Q1 2026.

  • Quarterly Goodwill & Intangibles rose 91.57% to $1.5 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Mar 2026, up 91.57% year-over-year, with the annual reading at $1.6 billion for FY2025, 90.78% up from the prior year.
  • Goodwill & Intangibles was $1.5 billion for Q1 2026 at Halozyme Therapeutics, down from $1.6 billion in the prior quarter.
  • Over five years, Goodwill & Intangibles peaked at $1.6 billion in Q4 2025 and troughed at $765.4 million in Q3 2025.
  • The 5-year median for Goodwill & Intangibles is $898.6 million (2023), against an average of $986.0 million.
  • Year-over-year, Goodwill & Intangibles fell 21.08% in 2023 and then skyrocketed 91.57% in 2026.
  • A 5-year view of Goodwill & Intangibles shows it stood at $955.7 million in 2022, then fell by 6.91% to $889.7 million in 2023, then dropped by 7.99% to $818.7 million in 2024, then skyrocketed by 90.78% to $1.6 billion in 2025, then dropped by 1.76% to $1.5 billion in 2026.
  • Per Business Quant, the three most recent readings for HALO's Goodwill & Intangibles are $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $765.4 million (Q3 2025).